Target Price | $97.32 |
Price | $69.44 |
Potential |
40.15%
register free of charge
|
Number of Estimates | 25 |
25 Analysts have issued a price target Biomarin Pharmaceutical 2026 .
The average Biomarin Pharmaceutical target price is $97.32.
This is
40.15%
register free of charge
$126.00
81.45%
register free of charge
$65.00
6.39%
register free of charge
|
|
A rating was issued by 30 analysts: 24 Analysts recommend Biomarin Pharmaceutical to buy, 6 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Biomarin Pharmaceutical stock has an average upside potential 2026 of
40.15%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Billion $ | 2.84 | 3.14 |
17.35% | 10.58% | |
EBITDA Margin | 22.06% | 28.29% |
78.58% | 28.26% | |
Net Margin | 14.85% | 19.27% |
114.00% | 29.78% |
25 Analysts have issued a sales forecast Biomarin Pharmaceutical 2025 . The average Biomarin Pharmaceutical sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Biomarin Pharmaceutical EBITDA forecast 2025. The average Biomarin Pharmaceutical EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
18 Biomarin Pharmaceutical Analysts have issued a net profit forecast 2025. The average Biomarin Pharmaceutical net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | 2.21 | 3.17 |
151.14% | 43.44% | |
P/E | 21.90 | |
EV/Sales | 4.06 |
18 Analysts have issued a Biomarin Pharmaceutical forecast for earnings per share. The average Biomarin Pharmaceutical <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the Biomarin Pharmaceutical stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Biomarin Pharmaceutical...
Analyst | Rating | Action | Date |
---|---|---|---|
Oppenheimer |
Locked
➜
Locked
|
Locked | Feb 24 2025 |
Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Feb 20 2025 |
B of A Securities |
Locked
➜
Locked
|
Locked | Feb 20 2025 |
RBC Capital |
Locked
➜
Locked
|
Locked | Feb 20 2025 |
Citigroup |
Locked
➜
Locked
|
Locked | Feb 20 2025 |
Scotiabank |
Locked
➜
Locked
|
Locked | Feb 20 2025 |
Piper Sandler |
Locked
➜
Locked
|
Locked | Feb 20 2025 |
Analyst Rating | Date |
---|---|
Locked
Oppenheimer:
Locked
➜
Locked
|
Feb 24 2025 |
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Feb 20 2025 |
Locked
B of A Securities:
Locked
➜
Locked
|
Feb 20 2025 |
Locked
RBC Capital:
Locked
➜
Locked
|
Feb 20 2025 |
Locked
Citigroup:
Locked
➜
Locked
|
Feb 20 2025 |
Locked
Scotiabank:
Locked
➜
Locked
|
Feb 20 2025 |
Locked
Piper Sandler:
Locked
➜
Locked
|
Feb 20 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.